21,406 Shares in Roivant Sciences Ltd. $ROIV Acquired by Truist Financial Corp

Truist Financial Corp acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,406 shares of the company’s stock, valued at approximately $465,000.

A number of other hedge funds have also recently added to or reduced their stakes in ROIV. Jones Financial Companies Lllp boosted its position in Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after purchasing an additional 1,148 shares during the period. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Bessemer Group Inc. boosted its position in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. Farther Finance Advisors LLC boosted its position in Roivant Sciences by 59.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,600 shares of the company’s stock worth $78,000 after purchasing an additional 1,345 shares during the period. Finally, Fifth Third Bancorp boosted its position in Roivant Sciences by 15.8% during the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock worth $94,000 after purchasing an additional 588 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Buying and Selling

In other news, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the completion of the sale, the director directly owned 15,804 shares of the company’s stock, valued at approximately $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Frank Torti sold 587,390 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the completion of the sale, the insider directly owned 13,736,547 shares of the company’s stock, valued at $377,892,407.97. This represents a 4.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,745,173 shares of company stock valued at $103,639,917 in the last ninety days. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Trading Down 1.2%

ROIV opened at $28.21 on Wednesday. Roivant Sciences Ltd. has a 1-year low of $10.59 and a 1-year high of $30.33. The stock has a market capitalization of $20.19 billion, a price-to-earnings ratio of -24.11 and a beta of 1.14. The business has a 50 day moving average of $28.38 and a 200-day moving average of $24.85.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ROIV shares. Citigroup upped their target price on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Guggenheim upped their target price on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, HC Wainwright upped their target price on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.55.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.